

Highlights of This Issue 5407

SPECIAL FEATURES

CCR 20th Anniversary Commentary

- 5409** CCR 20th Anniversary Commentary: Autologous T Cells—The Ultimate Personalized Drug for the Immunotherapy of Human Cancer
Steven A. Rosenberg

- 5412** CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma—Kinase Inhibition Redux
Diwakar Davar and John M. Kirkwood

CCR Translations

- 5415** Optimizing Anti-EGFR Therapy in Colorectal Cancer
Ramon Salazar and Fortunato Ciardiello
See related article, p. 5469
- 5417** Releasing the Brake on Oncolytic Viral Therapy
Clare Y. Slaney and Phillip K. Darcy
See related article, p. 5543

CCR Drug Updates

- 5420** Lenvatinib in Advanced, Radioactive Iodine–Refractory, Differentiated Thyroid Carcinoma
Kay T. Yeung and Ezra E.W. Cohen

Molecular Pathways

- 5427** Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
Lijie Zhai, Stefani Spranger, David C. Binder, Galina Gritsina, Kristen L. Lauing, Francis J. Giles, and Derek A. Wainwright
- 5434** Molecular Pathways: Fatty Acid Synthase
Suzanne F. Jones and Jeffrey R. Infante

Review

- 5439** ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non–Small Cell Lung Cancer



Ramaswamy Govindan, Sumithra J. Mandrekar, David E. Gerber, Geoffrey R. Oxnard, Suzanne E. Dahlberg, Jamie Chaft, Shakun Malik, Margaret Mooney, Jeffrey S. Abrams, Pasi A. Jänne, David R. Gandara, Suresh S. Ramalingam, and Everett E. Vokes

CANCER THERAPY: CLINICAL

- 5445** Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337)
Gregory N. Dietsch, Tressa D. Randall, Raphael Gottardo, Donald W. Northfelt, Ramesh K. Ramanathan, Peter A. Cohen, Kristi L. Manjarrez, Mona Newkirk, James Kyle Bryan, and Robert M. Hershberg

PERSONALIZED MEDICINE AND IMAGING

- 5453** Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
Christoffer Gebhardt, Alexandra Sevko, Huanhuan Jiang, Ramtin Lichtenberger, Maïke Reith, Kathrin Tarnanidis, Tim Holland-Letz, Ludmila Umansky, Philipp Beckhove, Antje Sucker, Dirk Schadendorf, Jochen Utikal, and Viktor Umansky
- 5460** Identification of Biomarkers Including ¹⁸F-DG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Olivier Humbert, Jean-Marc Riedinger, Céline Charon-Barra, Alina Berriolo-Riedinger, Isabelle Desmoulins, Véronique Lorgis, Salim Kanoun, Charles Coutant, Pierre Fumoleau, Alexandre Cochet, and François Brunotte
- 5469** Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer
Marc Peeters, Kelly S. Oliner, Timothy J. Price, Andrés Cervantes, Alberto F. Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J.A. Punt, Andrew H. Strickland, Gregory Wilson, Tudor E. Ciuleanu, Laslo Roman, Eric Van Cutsem, Pei He, Hua Yu, Reija Koukakis, Jan-Henrik Terwey, Andre S. Jung, Roger Sidhu, and Scott D. Patterson
See related commentary, p. 5415

Table of Contents

- 5480** Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study
Krishnansu S. Tewari, Michael W. Sill, Bradley J. Monk, Richard T. Penson, Harry J. Long III, Andrés Poveda, Lisa M. Landrum, Mario M. Leitao, Jubilee Brown, Thomas J.A. Reid, Helen E. Michael, and David H. Moore

CANCER THERAPY: PRECLINICAL

- 5488** Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy
Marta Paez-Ribes, Shan Man, Ping Xu, and Robert S. Kerbel
- 5499** MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer
Celina García-García, Martín A. Rivas, Yasir H. Ibrahim, María Teresa Calvo, Albert Gris-Oliver, Olga Rodríguez, Judit Grueso, Pilar Antón, Marta Guzmán, Claudia Aura, Paolo Nuciforo, Katti Jessen, Guillem Argilés, Rodrigo Dienstmann, Andrea Bertotti, Livio Trusolino, Judit Matito, Ana Vivancos, Irene Chicote, Héctor G. Palmer, Josep Tabernero, Maurizio Scaltriti, José Baselga, and Violeta Serra
- 5511** Preclinical Assessment of Efficacy of Radiation Dose Painting Based on Intratumoral FDG-PET Uptake
Daniela Trani, Ala Yaromina, Ludwig Dubois, Marlies Granzier, Sarah G.J.A. Peeters, Rianne Biemans, Georgi Nalbantov, Natasja Lieuwes, Brigitte Reniers, Esther E.G.C. Troost, Frank Verhaegen, and Philippe Lambin
- 5519** Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas
Simonetta M. Leto, Francesco Sassi, Irene Catalano, Valter Torri, Giorgia Migliardi, Eugenia R. Zanella, Mark Throsby, Andrea Bertotti, and Livio Trusolino
- 5532** NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma
Junwei Huang, Yi Zhou, Gregory S. Thomas, Zhimin Gu, Ye Yang, Hongwei Xu, Guido Tricot, and Fenghuang Zhan
- 5543** Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
Juan J. Rojas, Padma Sampath, Weizhou Hou, and Steve H. Thorne
See related commentary, p. 5417

- 5552** Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma
Minh Nguyen, Shuichi Miyakawa, Junichi Kato, Toshiyuki Mori, Toshimitsu Arai, Mark Armanini, Karen Gelmon, Rinat Yerushalmi, Samuel Leung, Dongxia Gao, Gregory Landes, Mary Haak-Frendscho, Kathleen Elias, and Andrew D. Simmons

- 5563** The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)



Francesca Vena, Eleonora Li Causi, Manuel Rodriguez-Justo, Samantha Goodstal, Thorsten Hagemann, John A. Hartley, and Daniel Hochhauser

- 5578** Cabozantinib Inhibits Abiraterone's Upregulation of IGF1R Phosphorylation and Enhances Its Anti-Prostate Cancer Activity
Xiaodong Wang, Ying Huang, Amanda Christie, Michaela Bowden, Gwo-Shu Mary Lee, Philip W. Kantoff, and Christopher J. Sweeney

- 5588** Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts
Magdalena Bieniasz, Parvathi Radhakrishnan, Najme Faham, Jean-Paul De La O, and Alana L. Welm

BIOLOGY OF HUMAN TUMORS

- 5601** SH3BGRL3 Protein as a Potential Prognostic Biomarker for Urothelial Carcinoma: A Novel Binding Partner of Epidermal Growth Factor Receptor
Cheng-Yao Chiang, Chin-Chen Pan, Hong-Yi Chang, Ming-Derg Lai, Tzong-Shin Tzai, Yuh-Shyan Tsai, Pin Ling, Hsiao-Sheng Liu, Bi-Fang Lee, Hong-Ling Cheng, Chung-Liang Ho, Shu-Hui Chen, and Nan-Haw Chow
- 5612** Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the Pancreas
Edgar Ben-Josef, Asha George, William F. Regine, Ross Abrams, Meredith Morgan, Dafydd Thomas, Paul L. Schaefer, Thomas A. DiPetrillo, Mitchel Fromm, William Small Jr, Samir Narayan, Kathryn Winter, Kent A. Griffith, Chandan Guha, and Terence M. Williams
- 5619** Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas
Harrison Tsai, Carlos L. Morais, Mohammed Alshalalfa, Hsueh-Li Tan, Zaid Haddad, Jessica Hicks, Nilesh Gupta, Jonathan I. Epstein, George J. Netto, William B. Isaacs, Jun Luo, Rohit Mehra, Robert L. Vessella, R. Jeffrey Karnes, Edward M. Schaeffer, Elai Davicioni, Angelo M. De Marzo, and Tamara L. Lotan

Table of Contents

5630 Pretreatment microRNA Expression Impacting on Epithelial-to-Mesenchymal Transition Predicts Intrinsic Radiosensitivity in Head and Neck Cancer Cell Lines and Patients

Monique C. de Jong, Jelle J. ten Hoeve, Reidar Grénman, Lodewyk F. Wessels, Ron Kerkhoven, Hein te Riele, Michiel W.M. van den Brekel, Marcel Verheij, and Adrian C. Begg

LETTERS TO THE EDITOR

5639 Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib—Letter

Olivier Huillard, Florence Tenenbaum, Jerome Clerc, Francois Goldwasser, and Lionel Groussin

5640 Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib—Response

S. Michael Rothenberg, Gilbert H. Daniels, and Lori J. Wirth

5642 Infliximab for IPILIMUMAB-Related Colitis—Letter

Eduar Arriola, Matthew Wheeler, Ioannis Karydis, Gareth Thomas, and Christian Ottensmeier

5644 Cervical Cancer Prevention and Cancer Control in Latin America—Letter

Tatiana Vidaurre

5646 Acknowledgment to Reviewers


 AC icon indicates Author Choice

 CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows an image of tricolor immunofluorescent staining of a representative tumor from a patient with pancreatic adenocarcinoma. The tissue is stained for GSK3 β (red), cytokeratin 8 (green), and counterstained for DAPI. For details, see the article by Ben-Josef and colleagues on page 5612 of this issue.



Clinical Cancer Research

21 (24)

Clin Cancer Res 2015;21:5407-5654.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/21/24>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/21/24>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.